BridgeMD
Compares treatment options for Lignocaine
Official title Lignocaine vs Bupivacaine Infiltration for Postpartum Perineal Pain After Vaginal Delivery With Episiotomy in Primigravidae
ClinicalTrials.gov ID: NCT06568289
What this study is testing
What is Lignocaine?
Lignocaine is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for lignocaine.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- In this study, we will compare the effect and safety of lignocaine versus bupivacaine infiltration for postpartum perineal pain after vaginal delivery with episiotomy in primigravidae.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 40, women only
You may be able to join if
- Primigravidae with the full term undergoing vaginal delivery with episiotomy.
- Pregnancies and singleton vertex cephalic fetuses.
- In the active phase of the first stage of labor.
You likely can't join if
- Patients with history of drug allergies to study drugs as this will increase the risk of complications.
- Patients undergoing vaginal delivery under epidural or spinal anesthesia as they will affect post-operative pain and interfere with assessment of how...
- Evidence of local infection at site of injection as this will interfere with the action of the study drug and will increase the risk of complications.
- Inability to cooperate as this will affect our assessment.
- Patient's refusal.
- Any intraoperative complications that will affect our outcome criteria (bleeding, organ injury) as they will affect patient's vital data and affect...
See the full eligibility criteria
- Primigravidae with the full term undergoing vaginal delivery with episiotomy.
- Pregnancies and singleton vertex cephalic fetuses.
- In the active phase of the first stage of labor.
- Patients with history of drug allergies to study drugs as this will increase the risk of complications.
- Patients undergoing vaginal delivery under epidural or spinal anesthesia as they will affect post-operative pain and interfere with assessment of how well it works of local infiltration of the study drugs.
- Evidence of local infection at site of injection as this will interfere with the action of the study drug and will increase the risk of complications.
- Inability to cooperate as this will affect our assessment.
- Patient's refusal.
- Any intraoperative complications that will affect our outcome criteria (bleeding, organ injury) as they will affect patient's vital data and affect our assessment.
- Neurological comorbidities (chronic pain disorder, chronic systemic disease, neurological disorder, neuropathic pain) as they will need more analgesia.
- Drug abuse as they will be tolerant to the used analgesics.
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 40 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.